Adriana Pop Moody
Rheumatology · Corpus Christi, TXNPI 1700919719
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 509 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,943 and has fallen 61.3% since, to $1,527 in 2022.
Across 509 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- E.r. Squibb & Sons, L.L.C.$862
- AbbVie$757
- Pfizer$576
- Sanofi$516
- Mallinckrodt Hospital Products Inc.$455
- plus $4K from 19 others
Across 189 payments — averaging $3114.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$239K
- UCB SA$113K
- Gilead$93K
- GSK$81K
- Janssen Research & Development, LLC$51K
- Pfizer$11K
What the payments were for
- Food & beverage$8,73997%
- Education$2963%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 130 | $2,107 |
| E.r. Squibb & Sons, L.L.C. | 77 | $862 |
| AbbVie | 50 | $757 |
| Pfizer | 46 | $576 |
| Sanofi | 7 | $516 |
| Mallinckrodt Hospital Products Inc. | 18 | $455 |
| GSK | 19 | $425 |
| UCB, Inc. | 23 | $418 |
| Novartis | 22 | $402 |
| Aurinia Pharma U.S., Inc. | 14 | $388 |
| Genentech USA, Inc. | 18 | $381 |
| Lilly USA, LLC | 24 | $380 |
| Johnson & Johnson(2 entities) | 17 | $277 |
| Radius Health, Inc. | 7 | $212 |
| Sanofi-aventis U.S. LLC | 2 | $184 |
| Actelion Pharmaceuticals US, Inc. | 6 | $136 |
| AstraZeneca(2 entities) | 4 | $134 |
| Merck | 7 | $102 |
| ANI Pharmaceuticals, Inc. | 4 | $80 |
| Mallinckrodt Enterprises LLC | 4 | $78 |
| Arbor Pharmaceuticals, Inc. | 3 | $53 |
| Genentech, Inc. | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Pacira Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,035 in reported general payments places this provider in the 65th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Corpus Christi
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.